The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results.

Michelle L O'DonoghueRobert S RosensonJ Antonio G LópezNorman E LeporSeth J BaumElmer StoutDaniel GaudetBeat KnuselJulia F KuderSabina A MurphyHuei WangYou WuTrupti ShahJingying WangTomasz WilmanskiWinnie SohnHelina KassahunMarc S Sabatinenull null

Published in: Journal of the American College of Cardiology (2024)

Olpasiran is a potent siRNA with prolonged effects on Lp(a) lowering. Participants receiving doses ≥75 mg Q12W sustained a ∼40% to 50% reduction in Lp(a) levels close to 1 year after the last dose. (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study [OCEAN(a)-DOSE]; NCT04270760).

Keyphrases

cardiovascular events
cardiovascular disease
drug delivery
low density lipoprotein
combination therapy
hyaluronic acid